Covered recipient · General Payments record
SHAHID RAFIQ
Allopathic & Osteopathic Physicians Neuromusculoskeletal Medicine & OMM
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$2,031.42
122 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $2,031.42 | 122 |
By paying entity
PY2021 · entire year · sorted by reported total
Page 3 of 3; records 101–122 of 122 matching records. This page contains 22 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
SHAHID RAFIQ
NPI 1447214549 · CMS profile ID 338035
Allopathic & Osteopathic Physicians / Neuromusculoskeletal Medicine & OMM
FREDERICK, MD
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 3; records 101–122 of 122 matching records. This page contains 22 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1447214549?year=2021&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- SHAHID RAFIQ, NPI 1447214549, CMS profile ID 338035. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–122 of 122 matching records. This page contains 22 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1447214549?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). SHAHID RAFIQ, NPI 1447214549, CMS profile ID 338035. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–122 of 122 matching records. This page contains 22 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1447214549?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- SHAHID RAFIQ, NPI 1447214549, CMS profile ID 338035, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–122 of 122 matching records. This page contains 22 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1447214549?year=2021&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
122 matching records · $2,031.42 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–122 of 122.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| AbbVie Inc. | $17.34 | 02/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795751453 | CMS |
| E.R. Squibb & Sons, L.L.C. | $13.58 | 02/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783574337 | CMS |
| AbbVie Inc. | $13.83 | 02/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795751447 | CMS |
| Neurelis, Inc. | $17.63 | 02/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 842876789 | CMS |
| Novartis Pharmaceuticals Corporation | $1.58 | 02/10/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 813181975 | CMS |
| Sunovion Pharmaceuticals Inc. | $22.40 | 02/10/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 821591667 | CMS |
| Sunovion Pharmaceuticals Inc. | $22.40 | 02/10/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 821591673 | CMS |
| E.R. Squibb & Sons, L.L.C. | $15.82 | 02/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783574327 | CMS |
| Allergan, Inc. | $6.02 | 02/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 792914335 | CMS |
| AbbVie Inc. | $17.95 | 02/05/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795751435 | CMS |
| AbbVie Inc. | $4.38 | 02/05/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795751441 | CMS |
| Novartis Pharmaceuticals Corporation | $12.86 | 01/29/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 813181979 | CMS |
| AbbVie Inc. | $14.41 | 01/28/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795751429 | CMS |
| Neurelis, Inc. | $15.18 | 01/26/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 842876785 | CMS |
| AbbVie Inc. | $2.21 | 01/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795751423 | CMS |
| Amgen Inc. | $19.39 | 01/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 825780441 | CMS |
| Allergan, Inc. | $13.58 | 01/16/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 792914333 | CMS |
| Teva Pharmaceuticals USA, Inc. | $20.29 | 01/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 839698583 | CMS |
| Allergan, Inc. | $13.82 | 01/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 792914331 | CMS |
| Sunovion Pharmaceuticals Inc. | $22.93 | 01/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 821579533 | CMS |
| Amgen Inc. | $27.43 | 01/05/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 825780437 | CMS |
| E.R. Squibb & Sons, L.L.C. | $15.04 | 01/04/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783574321 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $591,294.79 | 50 |
| PY2024 | Principal investigator | $236,963.75 | 13 |
| PY2023 | Principal investigator | $139,146.77 | 9 |
| PY2022 | Principal investigator | $9,746.21 | 1 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
50 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Ipsen Innovation | $801.09 | 12/24/2025 | Non-covered Recipient Entity Comprehensive Neurology Services, Pa | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184288760 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,789.00 | 12/24/2025 | Non-covered Recipient Entity Comprehensive Nrlgy Svcs | A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE (LIBREXIA-STROK) | No dispute reported | 06/30/2026 | 1175228077 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,685.00 | 12/17/2025 | Non-covered Recipient Entity Comprehensive Nrlgy Svcs | A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE (LIBREXIA-STROK) | No dispute reported | 06/30/2026 | 1175228130 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $60.00 | 12/01/2025 | Non-covered Recipient Entity COMPREHENSIVE NEUROLOGY SERVICES PA | A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of remibrutinib in patients with secondary progressive multiple sclerosis | No dispute reported | 06/30/2026 | 1190311335 |
| Principal investigator 1 | Janssen Research & Development, LLC | $13,552.00 | 11/14/2025 | Non-covered Recipient Entity Comprehensive Nrlgy Svcs | A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE (LIBREXIA-STROK) | No dispute reported | 06/30/2026 | 1175228114 |
| Principal investigator 1 | Ipsen Innovation | $68.37 | 10/27/2025 | Non-covered Recipient Entity Comprehensive Neurology Services, Pa | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184288756 |
| Principal investigator 1 | Ipsen Innovation | $801.09 | 10/27/2025 | Non-covered Recipient Entity Comprehensive Neurology Services, Pa | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184288758 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,524.00 | 10/20/2025 | Non-covered Recipient Entity Comprehensive Nrlgy Svcs | A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE (LIBREXIA-STROK) | No dispute reported | 06/30/2026 | 1175228086 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $11,841.07 | 10/08/2025 | Non-covered Recipient Entity COMPREHENSIVE NEUROLOGY SERVICES PA | A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib | No dispute reported | 06/30/2026 | 1190311331 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $2,653.00 | 10/01/2025 | Non-covered Recipient Entity COMPREHENSIVE NEUROLOGY SERVICES PA | A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of remibrutinib in patients with secondary progressive multiple sclerosis | No dispute reported | 06/30/2026 | 1190311337 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,061.00 | 09/19/2025 | Non-covered Recipient Entity Comprehensive Nrlgy Svcs | A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE (LIBREXIA-STROK) | No dispute reported | 06/30/2026 | 1175228122 |
| Principal investigator 1 | Ipsen Innovation | $300.00 | 09/02/2025 | Non-covered Recipient Entity Comprehensive Neurology Services, Pa | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184288750 |
| Principal investigator 1 | Ipsen Innovation | $180.00 | 09/02/2025 | Non-covered Recipient Entity Comprehensive Neurology Services, Pa | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184288752 |
| Principal investigator 1 | Ipsen Innovation | $300.00 | 09/02/2025 | Non-covered Recipient Entity Comprehensive Neurology Services, Pa | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184288754 |
| Principal investigator 1 | Ipsen Innovation | $1,662.81 | 08/28/2025 | Non-covered Recipient Entity Comprehensive Neurology Services, Pa | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184288746 |
| Principal investigator 1 | Ipsen Innovation | $801.09 | 08/28/2025 | Non-covered Recipient Entity Comprehensive Neurology Services, Pa | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184288748 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,639.00 | 08/20/2025 | Non-covered Recipient Entity Comprehensive Nrlgy Svcs | A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE (LIBREXIA-STROK) | No dispute reported | 06/30/2026 | 1175228092 |
| Principal investigator 1 | Ipsen Innovation | $801.09 | 07/28/2025 | Non-covered Recipient Entity Comprehensive Neurology Services, Pa | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184288742 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,526.00 | 07/28/2025 | Non-covered Recipient Entity Comprehensive Nrlgy Svcs | A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE (LIBREXIA-STROK) | No dispute reported | 06/30/2026 | 1175228138 |
| Principal investigator 1 | Ipsen Innovation | $450.00 | 07/22/2025 | Non-covered Recipient Entity Comprehensive Neurology Services, Pa | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184288738 |
| Principal investigator 1 | Ipsen Innovation | $150.00 | 07/22/2025 | Non-covered Recipient Entity Comprehensive Neurology Services, Pa | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184288740 |
| Principal investigator 1 | Ipsen Innovation | $90.00 | 07/22/2025 | Non-covered Recipient Entity Comprehensive Neurology Services, Pa | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184288744 |
| Principal investigator 1 | Ipsen Innovation | $801.09 | 06/30/2025 | Non-covered Recipient Entity Comprehensive Neurology Services, Pa | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184288734 |
| Principal investigator 1 | Ipsen Innovation | $1,233.24 | 06/30/2025 | Non-covered Recipient Entity Comprehensive Neurology Services, Pa | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184288736 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,440.00 | 06/13/2025 | Non-covered Recipient Entity Comprehensive Nrlgy Svcs | A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE (LIBREXIA-STROK) | No dispute reported | 06/30/2026 | 1175228107 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,086.00 | 05/16/2025 | Non-covered Recipient Entity Comprehensive Nrlgy Svcs | A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE (LIBREXIA-STROK) | No dispute reported | 06/30/2026 | 1175228152 |
| Principal investigator 1 | Ipsen Innovation | $801.09 | 04/28/2025 | Non-covered Recipient Entity Comprehensive Neurology Services, Pa | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184288722 |
| Principal investigator 1 | Ipsen Innovation | $2,151.72 | 04/28/2025 | Non-covered Recipient Entity Comprehensive Neurology Services, Pa | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184288728 |
| Principal investigator 1 | Ipsen Innovation | $1,722.15 | 04/28/2025 | Non-covered Recipient Entity Comprehensive Neurology Services, Pa | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184288730 |
| Principal investigator 1 | Ipsen Innovation | $824.31 | 04/28/2025 | Non-covered Recipient Entity Comprehensive Neurology Services, Pa | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184288732 |
| Principal investigator 1 | Ipsen Innovation | $90.00 | 04/18/2025 | Non-covered Recipient Entity Comprehensive Neurology Services, Pa | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184288724 |
| Principal investigator 1 | Ipsen Innovation | $150.00 | 04/18/2025 | Non-covered Recipient Entity Comprehensive Neurology Services, Pa | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184288726 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,154.00 | 04/18/2025 | Non-covered Recipient Entity Comprehensive Nrlgy Svcs | A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE (LIBREXIA-STROK) | No dispute reported | 06/30/2026 | 1175228159 |
| Principal investigator 1 | Ipsen Innovation | $481.54 | 03/31/2025 | Non-covered Recipient Entity Comprehensive Neurology Services, Pa | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184288720 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,877.00 | 03/19/2025 | Non-covered Recipient Entity Comprehensive Nrlgy Svcs | A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE (LIBREXIA-STROK) | No dispute reported | 06/30/2026 | 1175228146 |
| Principal investigator 1 | Ipsen Innovation | $90.00 | 02/26/2025 | Non-covered Recipient Entity Comprehensive Neurology Services, Pa | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184288714 |
| Principal investigator 1 | Ipsen Innovation | $150.00 | 02/26/2025 | Non-covered Recipient Entity Comprehensive Neurology Services, Pa | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184288716 |
| Principal investigator 1 | Ipsen Innovation | $150.00 | 02/26/2025 | Non-covered Recipient Entity Comprehensive Neurology Services, Pa | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184288718 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,285.00 | 02/19/2025 | Non-covered Recipient Entity Comprehensive Nrlgy Svcs | A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE (LIBREXIA-STROK) | No dispute reported | 06/30/2026 | 1175230410 |
| Principal investigator 1 | Ipsen Innovation | $90.00 | 02/17/2025 | Non-covered Recipient Entity Comprehensive Neurology Services, Pa | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184288708 |
| Principal investigator 1 | Ipsen Innovation | $150.00 | 02/17/2025 | Non-covered Recipient Entity Comprehensive Neurology Services, Pa | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184288710 |
| Principal investigator 1 | Ipsen Innovation | $150.00 | 02/17/2025 | Non-covered Recipient Entity Comprehensive Neurology Services, Pa | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184288712 |
| Principal investigator 1 | Ipsen Innovation | $68.37 | 01/31/2025 | Non-covered Recipient Entity Comprehensive Neurology Services, Pa | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184288706 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $120.00 | 01/31/2025 | Non-covered Recipient Entity CLINRE COMPREHENSIVE NEUROLOGY | A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament Light | No dispute reported | 06/30/2026 | 1190314135 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,446.00 | 01/17/2025 | Non-covered Recipient Entity Comprehensive Nrlgy Svcs | A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE (LIBREXIA-STROK) | No dispute reported | 06/30/2026 | 1175228101 |
| Principal investigator 1 | Ipsen Innovation | $180.00 | 01/16/2025 | Non-covered Recipient Entity Comprehensive Neurology Services, Pa | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184288700 |
| Principal investigator 1 | Ipsen Innovation | $300.00 | 01/16/2025 | Non-covered Recipient Entity Comprehensive Neurology Services, Pa | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184288702 |
| Principal investigator 1 | Ipsen Innovation | $300.00 | 01/16/2025 | Non-covered Recipient Entity Comprehensive Neurology Services, Pa | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184288704 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $43,635.02 | 01/16/2025 | Non-covered Recipient Entity CLINRE COMPREHENSIVE NEUROLOGY | A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib | No dispute reported | 06/30/2026 | 1190312229 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $447,632.65 | 01/02/2025 | Non-covered Recipient Entity COMPREHENSIVE NEUROLOGY SERVICES PA | A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib | No dispute reported | 06/30/2026 | 1190311333 |